Growth hormone benefits children with 18q deletions

Jannine D. Cody, Margaret Semrud-Clikeman, L. Jean Hardies, Jack Lancaster, Patricia D. Ghidoni, Rebecca L. Schaub, Nora M. Thompson, Lynda Wells, John E. Cornell, Tanzy M. Love, Peter T. Fox, Robin J. Leach, Celia I. Kaye, Daniel E. Hale

Producción científica: Articlerevisión exhaustiva

20 Citas (Scopus)


Most individuals with constitutional deletions of chromosome 18q have developmental delays, dysmyelination of the brain, and growth failure due to growth hormone deficiency. We monitored the effects of growth hormone treatment by evaluating 23 individuals for changes in growth, nonverbal intelligence quotient (nIQ), and quantitative brain MRI changes. Over an average of 37 months, the treated group of 13 children had an average nIQ increase of 17 points, an increase in height standard deviation score of 1.7, and significant change in T1 relaxation times in the caudate and frontal white matter. Cognitive changes of this magnitude are clinically significant and are anticipated to have an effect on the long-term outcomes for the treated individuals.

Idioma originalEnglish (US)
Páginas (desde-hasta)9-15
Número de páginas7
PublicaciónAmerican Journal of Medical Genetics
Volumen137 A
EstadoPublished - ago 15 2005

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics


Profundice en los temas de investigación de 'Growth hormone benefits children with 18q deletions'. En conjunto forman una huella única.

Citar esto